Tango Therapeutics (NASDAQ:TNGX) Stock Rating Lowered by Wall Street Zen

Tango Therapeutics (NASDAQ:TNGX) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other brokerages have also weighed in on TNGX. Weiss Ratings reissued a “sell (e+)” rating on shares of Tango Therapeutics in a report on Wednesday, January 21st. Mizuho initiated coverage on Tango Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $19.00 target price on the stock. B. Riley Financial lifted their target price on Tango Therapeutics from $8.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Jefferies Financial Group reissued a “buy” rating and set a $18.00 price target on shares of Tango Therapeutics in a research report on Thursday. Finally, Wedbush raised their price objective on Tango Therapeutics from $15.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Tango Therapeutics Price Performance

Shares of TNGX stock opened at $16.95 on Friday. The firm has a fifty day moving average of $11.86 and a two-hundred day moving average of $9.48. The firm has a market cap of $2.42 billion, a P/E ratio of -19.48 and a beta of 1.76. Tango Therapeutics has a 1-year low of $1.03 and a 1-year high of $17.63.

Tango Therapeutics (NASDAQ:TNGX) last issued its earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. On average, sell-side analysts expect that Tango Therapeutics will post -1.19 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Daniella Beckman sold 10,317 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total transaction of $126,486.42. Following the completion of the transaction, the chief financial officer directly owned 184,297 shares of the company’s stock, valued at approximately $2,259,481.22. This represents a 5.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Barbara Weber sold 30,519 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $374,162.94. Following the sale, the director owned 1,629,254 shares in the company, valued at $19,974,654.04. The trade was a 1.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 113,633 shares of company stock valued at $1,420,857 over the last quarter. Insiders own 7.50% of the company’s stock.

Institutional Trading of Tango Therapeutics

Several hedge funds have recently made changes to their positions in TNGX. Invesco Ltd. grew its stake in Tango Therapeutics by 138.8% during the 1st quarter. Invesco Ltd. now owns 70,517 shares of the company’s stock worth $97,000 after buying an additional 40,983 shares during the last quarter. AQR Capital Management LLC bought a new stake in Tango Therapeutics in the first quarter valued at $195,000. Dynamic Technology Lab Private Ltd lifted its stake in Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after buying an additional 15,037 shares during the last quarter. Woodline Partners LP boosted its holdings in shares of Tango Therapeutics by 28.3% during the first quarter. Woodline Partners LP now owns 506,188 shares of the company’s stock valued at $693,000 after acquiring an additional 111,791 shares during the period. Finally, Jane Street Group LLC boosted its holdings in shares of Tango Therapeutics by 270.6% during the first quarter. Jane Street Group LLC now owns 352,897 shares of the company’s stock valued at $483,000 after acquiring an additional 257,668 shares during the period. Institutional investors own 78.99% of the company’s stock.

Tango Therapeutics News Roundup

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: Clinical collaboration with Erasca to test ERAS‑0015/vopimetostat in MTAP‑deleted, RAS‑mutant cancers expands Tango’s clinical footprint and creates near‑term partnership newsflow that likely drove buying interest and record highs. TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
• Positive Sentiment: HC Wainwright sharply raised its price target to $27 (buy), a large explicit upside that can boost sentiment and buy‑side conviction. HC Wainwright price target raise
• Positive Sentiment: Guggenheim raised its target to $20 and reiterated a buy rating, adding to analyst momentum and supporting the share‑price lift. Guggenheim price target raise
• Positive Sentiment: Wedbush raised its target to $19 with an “outperform” rating, another vote of confidence from sell‑side analysts that can attract new buyers. Wedbush price target raise
• Positive Sentiment: An investment firm added ~1.1M shares (~$9.5M), increasing its reported position materially — institutional buying that signals conviction and can underpin the rally. Investment Firm Bets Big on TNGX Stock
• Neutral Sentiment: Quarterly results beat EPS estimates by $0.02 (reported -$0.29 vs. -$0.31) — a modest positive but company remains unprofitable with negative margins and ROE, so financials are unlikely to change valuation narrative immediately. Tango Therapeutics press release
• Negative Sentiment: A Seeking Alpha piece warns against buying into the rally despite PRMT5 promise, highlighting clinical, competitive and valuation risks that could limit upside or prompt pullbacks if trial data or execution falter. Tango Therapeutics: I’m Not Buying Into Latest Rally

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.